Type 2 diabetes mellitus: safety and efficacy of evolocumab

  • Rosenson RS & al.
  • Diabetologia
  • 5 Apr 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • BANTING study demonstrated that in statin-treated patients with type 2 diabetes mellitus (T2DM) and hypercholesterolaemia or mixed dyslipidaemia, addition of evolocumab significantly reduced low-density lipoprotein-cholesterol (LDL-C) and non-high-density lipoprotein-cholesterol (non-HDL-C).
  • Evolocumab led to favourable changes in post-prandial chylomicrons, very LDL-C (VLDL-C) and LDL-C levels.

Why this matters

  • Several guidelines support more aggressive LDL-C lowering to levels
  • Findings support the efficacy and safety of evolocumab therapy in patients with T2DM and hyperlipidaemia or mixed dyslipidaemia.

Study design

  • Patients with T2DM (n=421) receiving maximally tolerated statin therapy were randomly assigned 2:1 to receive 12 weeks of monthly evolocumab 420 mg (n=280) and placebo (n=141).
  • Primary outcome: mean percentage change in LDL-C from baseline to 12 weeks and to the mean of 10 and 12 weeks.
  • Secondary outcome: mean percentage change in non-HDL-C, other lipids parameters, LDL-C
  • Funding: Amgen Inc.

Key results

  • At 12 and the mean of 10 and 12 weeks, evolocumab vs placebo showed a significant reduction in:
    • LDL-C level (mean difference [MD], 53.1% and 64.1%, respectively; P<.0001>
    • non-HDL-C level (MD, 46.3% and 56.6%, respectively; P<.0001>
  • Evolocumab significantly improved other lipid parameters, and a higher proportion of patients in evolocumab vs placebo group achieved LDL-C
  • Evolocumab showed favourable changes in chylomicron triacylglycerol and cholesterol, VLDL-C and LDL-C level after mixed-meal tolerance test vs placebo group (P<.05>
  • Evolocumab did not show any significant effects on glycaemic parameters and was safe and well tolerated.


  • Short-follow-up.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.